Johnston SR - Search Results

1

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Rugo HS, et al. Among authors: johnston sr. J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217461

2

Towards a molecular basis for tamoxifen resistance in breast cancer.

Johnston SR, Dowsett M, Smith IE. Johnston SR, et al. Ann Oncol. 1992 Jul;3(7):503-11. doi: 10.1093/oxfordjournals.annonc.a058251. Ann Oncol. 1992. PMID: 1498070 Free article. Review.

3

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Johnston SR, et al. Cancer Res. 1995 Aug 1;55(15):3331-8. Cancer Res. 1995. PMID: 7614468

4

Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.

Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE, Dowsett M. Johnston SR, et al. Eur J Cancer. 1994;30A(11):1663-9. doi: 10.1016/0959-8049(94)00327-2. Eur J Cancer. 1994. PMID: 7833141

5

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

6

Oestrogen receptor mutants and variants in breast cancer.

Dowsett M, Daffada A, Chan CM, Johnston SR. Dowsett M, et al. Among authors: johnston sr. Eur J Cancer. 1997 Jul;33(8):1177-83. doi: 10.1016/s0959-8049(97)00100-7. Eur J Cancer. 1997. PMID: 9301439 Review.

7

Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications.

Johnston SR. Johnston SR. Anticancer Drugs. 1997 Nov;8(10):911-30. doi: 10.1097/00001813-199711000-00002. Anticancer Drugs. 1997. PMID: 9436634 Review.

8

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

Newby JC, Johnston SR, Smith IE, Dowsett M. Newby JC, et al. Among authors: johnston sr. Clin Cancer Res. 1997 Sep;3(9):1643-51. Clin Cancer Res. 1997. PMID: 9815855

9

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Johnston SR, et al. Clin Cancer Res. 1999 Feb;5(2):251-6. Clin Cancer Res. 1999. PMID: 10037172

10

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Dowsett M, et al. Among authors: johnston sr. Clin Cancer Res. 1999 Sep;5(9):2338-43. Clin Cancer Res. 1999. PMID: 10499602 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters